Roche Pharma to Use Expression Pathology's Assays | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Expression Pathology said today that Roche will use its Liquid Tissue - SRM technology to identify molecular markers as part of its oncology drug programs.

The Rockville, Md.-based company said that it will provide Roche with multiplexed quantitative assays of cancer signaling pathway proteins and support their activation in formalin-fixed, paraffin-embedded samples for mass spectrometry analysis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.